Variantyx

Variantyx

Private
Framingham, MassachusettsHealthcare & Life Scienceswww.variantyx.com

Last Round

VC Round

Apr 26, 2024

Total Funding Raised

$88.5M

Company Overview

Variantyx is a biotechnology company that offers whole genome analytical technology for diagnosing and generating clinical reports on rare inherited disorders.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

whole-genome sequencingWGSgenomic testingmolecular diagnosticsrare genetic disordersprecision oncologyreproductive geneticsgenomic analysis platformnext-generation sequencingNGSbioinformatic solutionscancer genomicsdiagnostic yieldlong-read sequencinggenetic variant detectionprenatal testingpharma services

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Variantyx Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Variantyx Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
VC RoundApr 26, 2024
Series COct 18, 2023
DebtOct 18, 2022
Series C ExtensionFeb 14, 2022
Series CMar 15, 2021
Series B
Jun 6, 2019

Key People

Founding team and executive leadership

Haim Neerman

Co-Founder And CEO

Founding Team

Variantyx Investors

Notable investors and investment history

InvestorRounds
Kreos CapitalDebt
Bosch VenturesVC Round, Series C, Series C Extension
New Era Capital PartnersVC Round, Series C, Series B, Series C Extension
Peregrine Ventures (California)VC Round
IBM VenturesSeries C
GF Financial Markets (UK) LimitedSeries C
Quark Venture LPSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 14, 2025

    Launched proprietary Genomic Unity® testing platform for whole genome sequencing diagnostics.

  • Oct 14, 2025

    Company is a CLIA/CAP-certified genomics company.

Variantyx Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Variantyx Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Variantyx's valuation, stock price, and market status.

Firmographic Details

HeadquartersFramingham, Massachusetts
Employee Range221
Year Founded2014
Last FundingApr 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.